Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Optimal dose, duration and de-escalation of venetoclax in AML

Stéphane de Botton • 19 Sep 2026
Acute Myeloid Leukemia Leukemia Azacitidine Venetoclax

Stéphane De Botton, MD, PhD, Gustave Roussy Institute, Paris, France, presents the evidence for de-escalating venetoclax duration and optimizing dosing in venetoclax-azacitidine regimens for patients with acute myeloid leukemia (AML). Dr de Botton explains that hypomethylating agent (HMA) plus venetoclax regimens should be optimized for each patient, considering the evidence in older and unfit patients, genomic profile, and the potential addition of targeted therapies. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Stéphane de Botton

The challenges of predicting and diagnosing differentiation syndrome
2:24
The challenges of predicting and diagnosing differentiation syndrome
Stéphane de Botton • 19 Sep 2026
Differentiation syndrome in APL: parallels with IDH and menin inhibitors in AML
9:36
Differentiation syndrome in APL: parallels with IDH and menin inhibitors in AML
Stéphane de Botton • 18 Sep 2026
Current evidence base for de-escalating venetoclax in AML
1:00
Current evidence base for de-escalating venetoclax in AML
Stéphane de Botton • 18 Sep 2026
Combining differentiation therapy with BCL2 inhibition: impact on the DS risk profile
0:39
Combining differentiation therapy with BCL2 inhibition: impact on the DS risk profile
Stéphane de Botton • 18 Sep 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals